美国Fluzone高剂量疫苗十年公共卫生与经济收益估算
该研究基于决策树预算影响模型,模拟2010/11至2018/19九个流感季,从Medicare支付方视角估算高剂量三价流感疫苗(HD TIV)相比无HD TIV策略的公共卫生与经济收益,结果显示HD TIV避免了大量流感相关病例、就诊、住院和死亡,并产生净节约。
要点
- HD TIV在9个流感季估计避免1,333,479例流感病例和73,689例死亡。
- 住院费用占管理成本的98%以上,是主要成本驱动因素。
核心结论
- HD TIV的高效价转化为增加的避免健康和经济结局,自引入以来从支付方角度是节约成本的干预措施。
研究设计与样本
- 基于决策树框架的预算影响模型,应用于2010/11至2018/19共9个流感季,比较「有HD TIV」和「无HD TIV」两种策略。
主要发现
- HD TIV估计避免1,333,479例流感病例、769,476次就诊、40,004次急诊就诊、520,342次心肺住院和73,689例死亡。
- 「有HD TIV」策略中住院费用占管理成本的98.4%,「无HD TIV」策略中占98.3%。
关键数值与推荐
- 分析纳入ACIP自2010年推荐的流感疫苗:SD TIV、SD QIV、HD TIV、aTIV、ccQIV。
- HD TIV在所有情景分析中均保持成本节约。
临床怎么用
- 从Medicare支付方视角,HD TIV相比标准剂量三价疫苗可减少流感相关住院和死亡并节约成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to estimate the public health and economic benefits (from a Medicare perspective) of Fluzone High-Dose® in the US elderly population, since its introduction in 2010. METHODS: A budget impact model was developed using a decision tree framework and applied over 9 influenza seasons (2010/11 to 2018/19). The decision tree model was designed to capture influenza cases, hospitalizations possibly related to influenza or laboratory confirmed influenza, and influenza-related deaths. The analysis included influenza vaccines recommended by ACIP since 2010: SD TIV (trivalent), SD QIV (quadrivalent), HD TIV, aTIV (adjuvanted), ccQIV (cell-cultured). Two strategies were compared to evaluate the impact of HD TIV: a 'with HD TIV' strategy representative of the US vaccine landscape, and a 'without HD TIV' where the absence of HD TIV was modelled. Clinical and economic inputs were based on public US data from the CDC and national databases, while data on vaccine effectiveness were extracted from published literature and clinical trials. The impact of HD TIV was further explored in five scenario analyses and deterministic sensitivity analyses (DSA). RESULTS: Over 10 years, it is estimated that HD TIV resulted in an averted 1,333,479 influenza cases, 769,476 medical visits, 40,004 ED presentations, 520,342 cardiorespiratory hospitalizations and 73,689 deaths and generated an absolute $4.6 billion in savings, translating into a return on investment of 214.4%. Hospitalizations costs represented 98.4% and 98.3% of the management costs in the 'with HD TIV' strategy and 'without HD TIV' strategy respectively. Hospitalizations and HD TIV relative vaccine efficacy vs SD TIV as a major cost driver were further confirmed in scenario analysis and DSA. HD TIV remained cost saving under all the scenarios. CONCLUSION: The model showed that HD TIV higher efficacy translated into increased averted health and economic outcomes. HD TIV represented a cost saving intervention from a payer perspective since its introduction.
引用
- Net P, Colrat F, Nascimento Costa M, et al. Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States. Vaccine. 2021. PMID: 33509695. doi:10.1016/j.vaccine.2021.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。